José C.
- Country
- Portugal
- Department
- N/A
Research Overview
- A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
- A Phase 3 Randomized Double-Blind Trial of Risankizumab Versus Placebo in Patients with Active Psoriatic Arthritis and Prior Biologic Therapy Inadequacy
- A Phase 3 Randomized Double-Blind Study of Risankizumab Versus Placebo in Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy
Data & Insights
Has run more than one trial at 34 of 115 partner sites.
Specializations
Inflammatory Rheumatic Diseases
Clinical activity is centered on rheumatology, with involvement in studies of rheumatoid arthritis, psoriatic arthritis, juvenile psoriatic arthritis, giant cell arteritis, and erosive hand osteoarthritis. The portfolio also includes systemic sclerosis and diffuse cutaneous systemic sclerosis, reflecting a strong therapeutic focus on chronic immune-mediated joint and connective tissue disease.
- Rheumatoid arthritis
- Psoriatic arthritis
- Systemic sclerosis
- Giant cell arteritis
Research interest extends to systemic lupus erythematosus and Sjögren’s syndrome, supporting work across autoimmune disorders with musculoskeletal and systemic manifestations.
Inflammatory Bowel Disease
The investigator is engaged in therapeutic studies for Crohn’s disease and ulcerative colitis, including moderate to severe disease and long-term disease control. This area highlights a clear focus on immune-mediated gastrointestinal inflammation and advanced targeted treatment options.
- Crohn’s disease
- Ulcerative colitis
- Moderately to severely active inflammatory bowel disease
Additional involvement in pediatric and maintenance-oriented ulcerative colitis research broadens the therapeutic scope within chronic intestinal disease.
Fibrotic and Pulmonary Autoimmune Disease
Research activity includes interstitial lung disease secondary to systemic sclerosis and bronchiectasis, linking autoimmune inflammation with lung injury and respiratory morbidity. The landscape also encompasses fibrotic disease assessment in diffuse cutaneous systemic sclerosis.
- Systemic sclerosis–associated interstitial lung disease
- Diffuse cutaneous systemic sclerosis
- Bronchiectasis
These interests point to clinical engagement with progressive pulmonary complications and connective tissue disease–related organ involvement.
Metabolic and Cardiovascular Risk
The trial portfolio includes non-alcoholic steatohepatitis, type 2 diabetes with overweight, type 1 diabetes prevention and preservation of beta-cell function, as well as hypertension and atherosclerotic cardiovascular disease. This reflects interest in metabolic inflammation and cardiometabolic risk reduction.
- Non-alcoholic steatohepatitis
- Type 1 diabetes
- Type 2 diabetes
- Atherosclerotic cardiovascular disease
Studies also extend to high cardiovascular risk and chronic kidney disease, indicating involvement in overlapping systemic disease domains.
Supportive and Symptom-Driven Care
Additional clinical interest covers erosive esophagitis after gastrectomy, pancreatic exocrine insufficiency, upper limb spasticity after stroke or traumatic brain injury, and moderate to severe rotator cuff tendinopathy. These areas broaden the therapeutic landscape beyond immune disease into digestive, neurologic, and musculoskeletal symptom management.
- Erosive esophagitis
- Pancreatic exocrine insufficiency
- Upper limb spasticity
- Rotator cuff tendinopathy
The research profile also includes primary myelofibrosis and secondary myelofibrosis, adding hematologic disease to the investigator’s therapeutic interests.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.